Search - tctmd.com

Displaying 721 - 740 of 1006

Sort: Relevancy | Date

Presentation TCT 2015

Nerve Distribution Along the Renal Arteries: From the Branches to the Ostium

Presenter: Juan F. Granada, Michael Joner

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Presenter: C. Michael Gibson, Marco Valgimigli, Harvey D. White

October 11, 2015

Presentation TCT 2015

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Presenter: Gary M. Ansel, Michael R. Jaff, John R. Laird Jr

October 11, 2015

Presentation TCT 2015

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Presenter: Gary M. Ansel, Michael R. Jaff, Ravish Sachar

October 11, 2015

Presentation TCT 2015

Surgical LAA Closure: Patient Selection and Supporting Data

Presenter: David R. Holmes Jr., Vivek Y. Reddy, Michael Argenziano

October 11, 2015

Presentation TCT 2015

Debate: Fate of the Multidisciplinary Heart Valve Team as TAVR Becomes a TF-First Minimalist Procedure Inevitable Decline!

Presenter: Eberhard Grube, Michael J. Mack, Ganesh Manoharan

October 11, 2015

Presentation TCT 2015

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Presenter: Gary M. Ansel, Michael R. Jaff, William A. Gray

October 11, 2015

Presentation TCT 2015

Debate: Fate of the Multidisciplinary Heart Valve Team as TAVR Becomes a TF-First Minimalist Procedure That Would Be a Mistake!

Presenter: Eberhard Grube, Michael J. Mack, A. Pieter Kappetein

October 11, 2015

Presentation TCT 2015

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

Presenter: Gary M. Ansel, Michael R. Jaff, Lindsay S. Machan

October 11, 2015

Presentation TCT 2015

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Noninvasive Cardiologists Perspective

Presenter: Eberhard Grube, Michael J. Mack, Robert O. Bonow

October 11, 2015

Presentation TCT 2015

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

Presenter: Eberhard Grube, Michael J. Mack

October 11, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Uncontrolled Hypertension: Prevalence, Prognosis, and Treatment

Presenter: Ajay J. Kirtane, Felix Mahfoud, Michael A. Weber

October 11, 2015

Presentation TCT 2015

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Presenter: Gary M. Ansel, Michael R. Jaff

October 11, 2015

Presentation TCT 2015

Acute Coronary Syndrome: STEMI

Presenter: Peter Barlis, Greg L. Kaluza, Michael C. Kim

October 11, 2015

Presentation TCT 2015

How to Handle Outliers in the Lab

Presenter: Michael A. Kutcher, Sunil V. Rao

October 11, 2015

Presentation TCT 2015

Shining Light on the Sunshine Act

Presenter: Michael A. Kutcher, Sunil V. Rao, Peter L Duffy

October 11, 2015

News Conference News TCT 2015

Global TAVR Market Poised to Exceed DES Market by 2025

October 11, 2015

News Features TCT 2014

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

Todd Neale

October 31, 2014

News Features TCT 2014

Thoughtful Insights at TCT: Many Questions Remain Around Treatment of Valvular Disease

Todd Neale

October 24, 2014

Advertisement

Nerve Distribution Along the Renal Arteries: From the Branches to the Ostium

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Review and Perspectives of the Global Registry Data for Antiproliferative Therapies

Review of Multicenter, Randomized Outcomes Data of Antiproliferative Therapies: Zilver PTX, LEVANT II, In.PACT SFA, and DEFINITIVE AR

Surgical LAA Closure: Patient Selection and Supporting Data

Debate: Fate of the Multidisciplinary Heart Valve Team as TAVR Becomes a TF-First Minimalist Procedure Inevitable Decline!

Peering Through the Veil: Outcomes Reporting in SFA Intervention Decoded

Debate: Fate of the Multidisciplinary Heart Valve Team as TAVR Becomes a TF-First Minimalist Procedure That Would Be a Mistake!

Everything You Wanted to Know About Endovascular Radiation Hazards but Were Afraid to Ask

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Noninvasive Cardiologists Perspective

Pioneers Corner: Reflections on the Impact of TAVR on Aortic Valve Therapy (Now and in the Future) The Cardiac Surgeons Perspective

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Uncontrolled Hypertension: Prevalence, Prognosis, and Treatment

Is Peripheral Vascular Intervention Cost-effective? If So, From Whose Perspective?

Acute Coronary Syndrome: STEMI

How to Handle Outliers in the Lab

Shining Light on the Sunshine Act

Global TAVR Market Poised to Exceed DES Market by 2025

Thoughtful Insights at TCT: Tackling Resistant Hypertension, Long SFA Lesions, and Complex Carotid Disease

Thoughtful Insights at TCT: Many Questions Remain Around Treatment of Valvular Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content